Table 3. SBRT Outcomes in Patients with Known HPV Status.
Patient | HPV Status | Failure site(s) | Toxicity (grade) | Cancer Status | Smoking history | Concurrent cetuximab |
---|---|---|---|---|---|---|
1 | Negative | Lung | Hyperpigmentation1 | AWD | Yes | Yes |
2 | Negative | Local | None | AWD | Unknown | Unknown |
3 | Negative | Neck | Mucositis2, Dysgeusia1 | DOD | Yes | Yes |
4 | Negative | No change | None | DOD | No | Yes |
5 | Negative | Local | Unknown | DOD | Yes | Yes |
6 | Negative | No change | Dehydration2, Anemia2 | DOD | Yes | Yes |
7 | Negative | No change | Pain1 | DOD | Yes | Yes |
8 | Negative | Local | Pain1, Dysphagia2 | DOD | Yes | Yes |
9 | Negative | Local | Odynophagia3, Fatigue2 | DOD | Yes | Yes |
10 | Negative | Local, Neck, Lung | Odynophagia2, Dehydration3 | DOD | Yes | Yes |
11 | Negative | Local | Rash1, Dysphagia1 | DOD | Yes | Yes |
12 | Negative | Neck | Dysphagia1 | DOD | Yes | Yes |
13 | Negative | Local | Pain1 | DOD | Unknown | No |
14 | Positive | Maxilla, Lung | Xerostomia1 Mucositis2 | AWD | Unknown | No |
15 | Positive | Lung | Dysphagia1 | AWD | No | No |
16 | Positive | Mandible, Lung | Mucositis1 | AWD | No | Unknown |
17 | Positive | Local | Pain1 | AWD | No | Yes |
18 | Positive | No change | Dysgeusia2, Xerostomia2 | DOD | No | Yes |
19 | Positive | No change | Edema2 | DOD | No | Yes |
20 | Positive | Local, Neck | Unknown | DOD | Yes | No |
21 | Positive | Neck, Lung | None | DOD | Yes | No |
22 | Positive | Local | Mucositis1, Rash1 | DOD | Yes | Yes |
23 | Positive | Local, Neck, Lung | Mucositis2 | DOD | Yes | No |
24 | Positive | Lung | Mucositis1, Rash1 | DOD | Yes | No |
25 | Positive | Local | Pain1, Dysphagia2 | DOD | Yes | Yes |
26 | Positive | Lung | Unknown | DOD | No | Yes |
27 | Positive | Liver | Neck pain1, Arthralgia1 | DOD | No | No |
28 | Positive | Liver, Spleen | Non-healing wound of right neck3 | DOD | Yes | No |
29 | Positive | No change | Unknown | DOD | Yes | Unknown |
30 | Positive | Lung, Spine, Hip | Mucositis2 | DOD | No | Yes |